Dr. Ricardo Jorge Komotar, MD

Dr. Komotar practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Komotar's NPI, 1487803094, was assigned on September 18, 2008. Dr. Komotar graduated from The Johns Hopkins University School of Medicine in 2003. Dr. Komotar holds Florida license ME 110132.

Dr. Komotar's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Komotar's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Komotar is also affiliated with Boca Raton Regional Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Komotar to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Komotar practices, 7 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Komotar's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Komotar is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Komotar's licenses on file in 2 states: Florida and New York.

Dmand AI lists craniotomy among the conditions Dr. Komotar treats.

CMS data shows 854 Medicare services from Dr. Komotar across 19 procedure codes in 2024, for 402 Medicare patients. Medicare paid $375,534 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 402 Medicare patients who saw Dr. Komotar in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Komotar's median patient age at 70, with 61% women.

In 2024, Dr. Komotar wrote 78 Medicare Part D claims for 39 patients. 100% of them were for generic drugs. CMS names the drug for 49 of them, across 3 drugs with 11 or more claims each, at $485 in total drug cost. In 2023, CMS named 58 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Komotar for performance year 2024, reported as part of a group. Dr. Komotar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Komotar as offering telehealth.

Dmand AI links 484 papers to Dr. Komotar, published from 2004 to 2025. 2024 was the busiest year, with 30. The most frequent topics are Brain Neoplasms, Magnetic Resonance Imaging and Neurosurgical Procedures. Dr. Komotar has published most often in Neurosurgery. Dr. Komotar's most frequent co-authors are Michael Edward Ivan, MD, Ashish Harish Shah, MD and Robert M. Starke, MD.

Dmand AI links Dr. Komotar to 3 clinical trials. Conditions studied include Glioblastoma, Astrocytoma and Gliosarcoma.

CMS Open Payments shows 151 general payments to Dr. Komotar from 20 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Medtronic USA, Inc. paid the most, $33,205.

Dmand AI lists 18 awards for Dr. Komotar, most recently Best Doctors in America: American Health Council in 2018.

Dr. Komotar graduated from The Johns Hopkins University School of Medicine in 2003. Dr. Komotar is a member of AANS and CNS.

Dr. Komotar is in network with 11 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.